Development and Validation of an Immune-Related Prognostic Signature for Ovarian Cancer Based on Weighted Gene Coexpression Network Analysis

Figure 3

Validation of the prognostic signature with independent cohorts. (a) The high-risk group showed an unfavorable overall survival (OS) of ovarian cancer patients in the GSE26193 dataset using the Kaplan-Meier method. (b) In the GSE26193 dataset, the patients have been divided into two groups according to the risk scores. Compared with the low-risk group, the high-risk group showed an unfavorable progression-free survival of the ovarian cancer patients in the GSE26193 dataset using the Kaplan-Meier method. (c) In the GSE63885 dataset, the patients have been divided into two groups according to the risk scores. Compared with the low-risk groups, the high-risk group showed an unfavorable OS of the ovarian cancer patients in the GSE63885 dataset using the Kaplan-Meier method. (d) The high-risk group showed an unfavorable OS of ovarian cancer patients in the GSE18520 dataset using the Kaplan-Meier method.

(a)

(b)

(c)

(d)